<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>将其添加为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>Lantern Pharma Inc. (LTRN) 是一家临床阶段的生物技术公司，周三分享了其完成的 LP-184 一期剂量递增研究的更多细节和临床见解。</p>
<p>该试验在经过重度预处理的晚期实体瘤患者中显示出令人鼓舞的、持久的疾病控制，许多患者存在 DNA 损伤修复（DDR）通路缺陷。该研究满足了所有安全性和耐受性的主要终点。</p>
<p>Lantern 表示计划将 LP-184 推进到多个一期 b/二期临床试验中。</p>
<p>如需评论和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

LTRN

<p>Lantern Pharma Inc. 报告了其 LP-184 在晚期实体瘤的 1a 期研究中取得的积极结果，显示出在具有 DDR 通路缺陷的患者中具有持久的疾病控制。该研究达到了安全性和耐受性终点，Lantern 计划将 LP-184 推进至 1b/2 期试验</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>将其添加为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Lantern Pharma Inc. (LTRN), a clinical-stage biotechnology company, on Wednesday shared additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184.</p>
<div class="lb-trans"><p>Lantern Pharma Inc. (LTRN) 是一家临床阶段的生物技术公司，周三分享了其完成的 LP-184 一期剂量递增研究的更多细节和临床见解。</p>
</div><p>The trial showed encouraging, durable disease control in heavily pre-treated patients with advanced solid tumors, many of whom had DNA damage repair (DDR) pathway deficiencies. The study met all primary endpoints for safety and tolerability.</p>
<div class="lb-trans"><p>该试验在经过重度预处理的晚期实体瘤患者中显示出令人鼓舞的、持久的疾病控制，许多患者存在 DNA 损伤修复（DDR）通路缺陷。该研究满足了所有安全性和耐受性的主要终点。</p>
</div><p>Lantern said it plans to advance LP-184 into multiple Phase 1b/2 trials.</p>
<div class="lb-trans"><p>Lantern 表示计划将 LP-184 推进到多个一期 b/二期临床试验中。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如需评论和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

Lantern Pharma 公布 LP-184 在晚期实体瘤中的一期 a 期试验数据呈现积极结果